JPWO2019217780A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019217780A5 JPWO2019217780A5 JP2020562668A JP2020562668A JPWO2019217780A5 JP WO2019217780 A5 JPWO2019217780 A5 JP WO2019217780A5 JP 2020562668 A JP2020562668 A JP 2020562668A JP 2020562668 A JP2020562668 A JP 2020562668A JP WO2019217780 A5 JPWO2019217780 A5 JP WO2019217780A5
- Authority
- JP
- Japan
- Prior art keywords
- solvent
- nanoparticles
- solution
- plga
- microparticles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002904 solvent Substances 0.000 claims description 41
- 238000000034 method Methods 0.000 claims description 31
- 239000002105 nanoparticle Substances 0.000 claims description 28
- 239000002245 particle Substances 0.000 claims description 18
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims description 17
- 239000004480 active ingredient Substances 0.000 claims description 15
- 239000011859 microparticle Substances 0.000 claims description 14
- 239000004094 surface-active agent Substances 0.000 claims description 10
- 239000000839 emulsion Substances 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 229920000642 polymer Polymers 0.000 claims description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- 230000001804 emulsifying effect Effects 0.000 claims description 6
- 229920001308 poly(aminoacid) Polymers 0.000 claims description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 229920001577 copolymer Polymers 0.000 claims description 4
- 229920002643 polyglutamic acid Polymers 0.000 claims description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims description 3
- 229920000805 Polyaspartic acid Polymers 0.000 claims description 2
- 239000013504 Triton X-100 Substances 0.000 claims description 2
- 229920004890 Triton X-100 Polymers 0.000 claims description 2
- 238000013019 agitation Methods 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 125000002091 cationic group Chemical group 0.000 claims description 2
- -1 derivatives Polymers 0.000 claims description 2
- 238000004945 emulsification Methods 0.000 claims description 2
- 238000001704 evaporation Methods 0.000 claims description 2
- 230000008020 evaporation Effects 0.000 claims description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N glutamic acid Chemical compound OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 2
- 238000000265 homogenisation Methods 0.000 claims description 2
- 239000002563 ionic surfactant Substances 0.000 claims description 2
- 229930014626 natural product Natural products 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 2
- 229920001983 poloxamer Polymers 0.000 claims description 2
- 108700022290 poly(gamma-glutamic acid) Proteins 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 238000004140 cleaning Methods 0.000 claims 2
- 239000003093 cationic surfactant Substances 0.000 claims 1
- 239000002736 nonionic surfactant Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 239000002888 zwitterionic surfactant Substances 0.000 claims 1
- 229920000370 gamma-poly(glutamate) polymer Polymers 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862670204P | 2018-05-11 | 2018-05-11 | |
| US62/670,204 | 2018-05-11 | ||
| PCT/US2019/031659 WO2019217780A1 (en) | 2018-05-11 | 2019-05-10 | Microparticles and nanoparticles having negative surface charges |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021523151A JP2021523151A (ja) | 2021-09-02 |
| JP2021523151A5 JP2021523151A5 (https=) | 2022-05-17 |
| JPWO2019217780A5 true JPWO2019217780A5 (https=) | 2022-05-17 |
Family
ID=68468426
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020562668A Pending JP2021523151A (ja) | 2018-05-11 | 2019-05-10 | 負の表面電荷を有するマイクロ粒子及びナノ粒子 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20210169819A1 (https=) |
| EP (1) | EP3814272A4 (https=) |
| JP (1) | JP2021523151A (https=) |
| CA (1) | CA3098873A1 (https=) |
| WO (1) | WO2019217780A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021239983A1 (en) * | 2020-03-18 | 2022-09-22 | Flow Pharma, Inc. | Injectable formulation of poly(lactic-co-glycolic (PLGA)) microspheres encapsulating siltuximab |
| JP2023544419A (ja) | 2020-10-05 | 2023-10-23 | サイトダイム，インコーポレイテッド | Ｓｉｇｌｅｃ結合剤の医薬組成物 |
| CN115382476B (zh) * | 2022-07-26 | 2024-10-22 | 华东师范大学 | 一种超小粒径聚合物纳米颗粒的制备方法 |
| US20260053750A1 (en) * | 2022-08-17 | 2026-02-26 | Matthew Owen | Inhalable compositions of cdk9 inhibitors |
| CN115969796B (zh) * | 2022-12-06 | 2024-07-09 | 苏州大学 | 一种jak抑制剂长效微球及其制备方法与应用 |
| WO2025250539A1 (en) * | 2024-05-29 | 2025-12-04 | Cytodigm, Inc. | Pharmaceutical composition comprising sialic acid for treating diseases related to the lung |
| CN119033092B (zh) * | 2024-10-30 | 2024-12-24 | 恢春丹生物科技(海南)有限公司 | 一种蛹虫草灵芝孢子粉复合制剂及其应用 |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5021456A (en) | 1988-02-25 | 1991-06-04 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
| US4943593A (en) | 1988-02-25 | 1990-07-24 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
| US5059714A (en) | 1988-02-25 | 1991-10-22 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
| US5252608A (en) | 1988-02-25 | 1993-10-12 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
| US5182297A (en) | 1988-02-25 | 1993-01-26 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
| US4965288A (en) | 1988-02-25 | 1990-10-23 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
| US5120764A (en) | 1988-11-01 | 1992-06-09 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
| US4997854A (en) | 1989-08-25 | 1991-03-05 | Trustees Of Boston University | Anti-fibrotic agents and methods for inhibiting the activity of lysyl oxidase in-situ using adjacently positioned diamine analogue substrates |
| KR950700082A (ko) | 1992-02-28 | 1995-01-16 | 로버트 씨. 비숍 | 바이스탠더(bystander)에 의한 자가면역질환을 처치하는 방법 |
| AU5732296A (en) | 1995-05-08 | 1996-11-29 | Texas Biotechnology Corporation | Method for inhibiting the binding of selectins to sialyl-lew ises |
| US7759520B2 (en) | 1996-11-27 | 2010-07-20 | University Of Tennessee Research Foundation | Synthesis of selective androgen receptor modulators |
| US6995284B2 (en) | 2000-08-24 | 2006-02-07 | The University Of Tennessee Research Foundation | Synthesis of selective androgen receptor modulators |
| US20030232792A1 (en) | 2000-08-24 | 2003-12-18 | Dalton James T. | Selective androgen receptor modulators and methods of use thereof |
| US6838484B2 (en) | 2000-08-24 | 2005-01-04 | University Of Tennessee Research Foundation | Formulations comprising selective androgen receptor modulators |
| US20020173495A1 (en) | 2000-08-24 | 2002-11-21 | Dalton James T. | Selective androgen receptor modulators and methods of use thereof |
| US7026500B2 (en) | 2000-08-24 | 2006-04-11 | University Of Tennessee Research Foundation | Halogenated selective androgen receptor modulators and methods of use thereof |
| EP1401801B1 (en) | 2000-08-24 | 2006-11-02 | The University Of Tennessee Research Corporation | Selective androgen receptor modulators and methods of use thereof |
| US7253210B2 (en) | 2002-10-15 | 2007-08-07 | University Of Tennessee Research Foundation | Methylene-bridged selective androgen receptor modulators and methods of use thereof |
| US6998500B2 (en) | 2000-08-24 | 2006-02-14 | University Of Tennessee Research Foundation | Selective androgen receptor modulators and methods of use thereof |
| US20040260108A1 (en) | 2001-06-25 | 2004-12-23 | Dalton James T. | Metabolites of selective androgen receptor modulators and methods of use thereof |
| IL154425A0 (en) | 2000-08-24 | 2003-09-17 | Univ Tennessee Res H Corp | Selective androgen receptor modulators and methods of use thereof |
| US20030022868A1 (en) | 2001-06-25 | 2003-01-30 | Dalton James T. | Selective androgen receptor modulators and methods of use thereof |
| FR2828206B1 (fr) | 2001-08-03 | 2004-09-24 | Centre Nat Rech Scient | Utilisation d'inhibiteurs des lysyl oxydases pour la culture cellulaire et le genie tissulaire |
| US20060004042A1 (en) | 2001-08-23 | 2006-01-05 | Dalton James T | Formulations comprising selective androgen receptor modulators |
| WO2003057670A2 (en) | 2001-12-28 | 2003-07-17 | Guilford Pharmaceuticals Inc. | Indoles as naaladase inhibitors |
| US20030232013A1 (en) | 2002-02-22 | 2003-12-18 | Gary Sieckman | Therapeutic and diagnostic targeting of cancers cells with tumor homing peptides |
| EP1487458B1 (en) | 2002-02-28 | 2011-11-16 | University Of Tennessee Research Foundation | Multi-substituted selective androgen receptor modulators and methods of use thereof |
| CA2476657A1 (en) | 2002-02-28 | 2003-09-12 | The University Of Tennessee Research Corporation | Haloacetamide and azide substituted compounds and methods of use thereof |
| US7344700B2 (en) | 2002-02-28 | 2008-03-18 | University Of Tennessee Research Corporation | Radiolabeled selective androgen receptor modulators and their use in prostate cancer imaging and therapy |
| US7803970B2 (en) | 2002-02-28 | 2010-09-28 | University Of Tennessee Research Foundation | Multi-substitued selective androgen receptor modulators and methods of use thereof |
| GEP20074191B (en) | 2002-06-17 | 2007-09-10 | Univ Tennessee Res Foundation | N-bridged selective androgen receptor modulators and methods of use thereof |
| US7741371B2 (en) | 2002-06-17 | 2010-06-22 | University Of Tennessee Research Foundation | Selective androgen receptor modulators and methods of use thereof |
| US20040087810A1 (en) | 2002-10-23 | 2004-05-06 | Dalton James T. | Irreversible selective androgen receptor modulators and methods of use thereof |
| EP2457892A1 (en) | 2003-01-13 | 2012-05-30 | University of Tennessee Research Foundation | Large-scale synthesis of selective androgen receptor modulators |
| US20040167103A1 (en) | 2003-02-24 | 2004-08-26 | Dalton James T. | Haloacetamide and azide substituted compounds and methods of use thereof |
| SI2612862T1 (sl) | 2004-05-13 | 2017-04-26 | Icos Corporation | Kinazolini kot inhibitorji humane fosfatidilinozitol 3-kinaze delta |
| US20060258628A1 (en) | 2004-07-20 | 2006-11-16 | Steiner Mitchell S | Compositions comprising 5-alpha reductase inhibitors, and SARMs and methods of use thereof |
| US20090142345A1 (en) | 2005-03-15 | 2009-06-04 | Takeda Pharmaceutical Company Limited | Prophylactic/therapeutic agent for cancer |
| EP2136788B1 (en) | 2007-03-30 | 2011-10-26 | Bind Biosciences, Inc. | Cancer cell targeting using nanoparticles |
| CA2693310C (en) | 2007-08-02 | 2018-11-27 | Arresto Biosciences, Inc. | Lox and loxl2 inhibitors, antibodies and uses thereof |
| JP5841708B2 (ja) * | 2008-07-01 | 2016-01-13 | 日東電工株式会社 | 表面被覆微粒子の医薬組成物 |
| US8652843B2 (en) | 2008-08-12 | 2014-02-18 | Oncomed Pharmaceuticals, Inc. | DDR1-binding agents and methods of use thereof |
| JP2012503673A (ja) * | 2008-09-25 | 2012-02-09 | ティッシュ リジェネレーション システムズ インコーポレイテッド | ミネラルコーティングされたマイクロスフェア |
| US8450321B2 (en) | 2008-12-08 | 2013-05-28 | Gilead Connecticut, Inc. | 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor |
| US9532956B2 (en) * | 2009-04-18 | 2017-01-03 | Massachusetts Institute Of Technology | PH sensitive biodegradable polymeric particles for drug delivery |
| TWI491606B (zh) | 2009-07-13 | 2015-07-11 | Gilead Sciences Inc | 調節細胞凋亡信號之激酶的抑制劑 |
| US8680246B2 (en) | 2010-02-04 | 2014-03-25 | Gilead Biologics, Inc. | Antibodies that bind to lysyl oxidase-like 2 (LOXL2) |
| KR101930179B1 (ko) | 2010-08-27 | 2018-12-17 | 길리아드 바이오로직스, 인크. | 매트릭스 메탈로프로테이나제 ９에 대한 항체 |
| JP5909745B2 (ja) * | 2010-11-12 | 2016-04-27 | クール ファーマシューティカルズ ディベロップメント カンパニー | 炎症性疾患の治療薬、ならびにウイルスまたは細菌感染疾患の治療薬 |
| WO2013027802A1 (ja) | 2011-08-23 | 2013-02-28 | 中外製薬株式会社 | 抗腫瘍活性を有する新規な抗ｄｄｒ１抗体 |
| GB201115529D0 (en) | 2011-09-08 | 2011-10-26 | Imp Innovations Ltd | Antibodies, uses and methods |
| JP2014528451A (ja) | 2011-10-04 | 2014-10-27 | ギリアード カリストガ エルエルシー | Ｐｉ３ｋの新規キノキサリン阻害剤 |
| UY34573A (es) | 2012-01-27 | 2013-06-28 | Gilead Sciences Inc | Inhibidor de la quinasa que regula la señal de la apoptosis |
| WO2013116562A1 (en) | 2012-02-03 | 2013-08-08 | Gilead Calistoga Llc | Compositions and methods of treating a disease with (s)-4 amino-6-((1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile |
| CN102690399B (zh) | 2012-06-14 | 2013-07-31 | 太原理工大学 | 聚天冬氨酸/聚丙烯酸共聚物互穿网络水凝胶及其制备方法 |
| WO2013192532A2 (en) * | 2012-06-21 | 2013-12-27 | Northwestern University | Peptide conjugated particles |
| UY35044A (es) | 2012-09-24 | 2014-04-30 | Gilead Sciences Inc | ANTICUERPOS ANTI-dDr1 |
| EP2928500B1 (en) | 2012-12-04 | 2019-03-06 | Phosphorex Inc. | Microparticles and nanoparticles having negative surface charges |
| JP6207100B2 (ja) | 2012-12-21 | 2017-10-04 | ギリアード カリストガ エルエルシー | イソキノリノンまたはキナゾリノンホスファチジルイノシトール３−キナーゼ阻害剤 |
| NZ708864A (en) | 2012-12-21 | 2016-09-30 | Gilead Calistoga Llc | Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors |
| CN105263476A (zh) | 2013-03-13 | 2016-01-20 | 库尔制药开发公司 | 用于治疗炎症的免疫修饰性颗粒 |
| ES2667173T3 (es) | 2013-06-14 | 2018-05-09 | Gilead Calistoga Llc | Inhibidores de fosfatidilinositol 3-quinasa |
| US9290505B2 (en) | 2013-12-23 | 2016-03-22 | Gilead Sciences, Inc. | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors |
| IL260074B2 (en) | 2015-12-23 | 2026-01-01 | Cour Pharmaceuticals Dev Company Inc | Covalent polymer-antigen particle conjugates |
-
2019
- 2019-05-10 JP JP2020562668A patent/JP2021523151A/ja active Pending
- 2019-05-10 WO PCT/US2019/031659 patent/WO2019217780A1/en not_active Ceased
- 2019-05-10 CA CA3098873A patent/CA3098873A1/en not_active Abandoned
- 2019-05-10 EP EP19799971.7A patent/EP3814272A4/en not_active Withdrawn
-
2020
- 2020-11-10 US US17/093,785 patent/US20210169819A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021523151A5 (https=) | ||
| US20230126007A1 (en) | Nanoparticles encapsulating soluble biologics, therapeutics, and imaging agents | |
| Dinarvand et al. | Effect of surfactant HLB and different formulation variables on the properties of poly-D, L-lactide microspheres of naltrexone prepared by double emulsion technique | |
| Hu et al. | Synthesis and characterization of chitosan–poly (acrylic acid) nanoparticles | |
| Mao et al. | Self-assembled polyelectrolyte nanocomplexes between chitosan derivatives and insulin | |
| Lassalle et al. | PLA nano‐and microparticles for drug delivery: an overview of the methods of preparation | |
| Tiyaboonchai | Chitosan nanoparticles: a promising system for drug delivery | |
| Kunda et al. | Bovine Serum Albumin Adsorbed PGA-co-PDL Nanocarriers for Vaccine Delivery via Dry Powder Inhalation: Kunda et al. | |
| US8821932B2 (en) | Pharmaceutical compositions | |
| Seremeta et al. | Development and characterization of benznidazole nano-and microparticles: a new tool for pediatric treatment of Chagas disease? | |
| Masotti et al. | Chitosan micro-and nanospheres: fabrication and applications for drug and DNA delivery | |
| Csaba et al. | Design and characterisation of new nanoparticulate polymer blends for drug delivery | |
| JP2022546559A (ja) | 櫛形ポリマーおよびブロックコポリマーで安定化された、核酸および他の可溶性親水性化合物を封入するナノ粒子 | |
| JP5575667B2 (ja) | 薬物の投与のためのナノ粒子キャリア及びその製造方法 | |
| CN103249406A (zh) | 一种用于制备改进的组合物的方法 | |
| Rawat et al. | Influence of selected formulation variables on the preparation of enzyme-entrapped Eudragit S100 microspheres | |
| JPWO2019217780A5 (https=) | ||
| CN112972388A (zh) | 卡利拉嗪释放制剂 | |
| CA2713750A1 (en) | Preparation of nanoparticles by using a vibrating nozzle device | |
| US20220211637A1 (en) | Random copolymer stabilized nanoparticles encapsulating soluble hydrophilic compounds | |
| CN107106504B (zh) | 释放纳米粒子的肠溶微米粒子的制备 | |
| Chaw et al. | Water-soluble betamethasone-loaded poly (lactide-co-glycolide) hollow microparticles as a sustained release dosage form | |
| US20060153923A1 (en) | Nanoparticles of polypoxyethylenated derivatives | |
| Tamayo-Esquivel et al. | Evaluation of the enhanced oral effect of omapatrilat-monolein nanoparticles prepared by the emulsification-diffusion method | |
| Winter de Vargas et al. | Strategies used for to improve aqueous solubility of simvastatin: a systematic review. |